Prof Raoult’s web site hosts an interesting map, under the title, “Pays où l’hydroxychloroquine est recommandée”:
India, of course, has the further approval for prophylaxis.
That’s significant, as talk on vaccines tends to point to 12 – 18 months and double-blind, placebo controlled tests in progress or about to start in the US look likely to take more than a year.
Meanwhile, OWID tracks how time to double to current number of deaths — probably the best statistic — is continuing to stretch out:
(Notice, the S-curves and driving impulses.)
Likewise, we can see the daily cases clearly peaking (for THIS wave . . . notice, Wave 2 for China and even an uptick to a Wave 3):
This is then reflected in the cumulative cases curves:
Oddly, Japan and Singapore seem to be tracking on a double in ten days exponential growth path with superposed wobbling, i.e. sub-waves, so they have apparently flattened rather than eliminated the curve.
The issue now switches to the race between costs and damage due to the disease vs costs and damage due to economic and social impacts of attempted suppressive measures. Recall, recessions and depressions also cost lives.
We need to draw lessons and prepare for the obvious emergent age of pandemics. END